Skip to content
AnalystLens

Roivant Sciences 8-K Report, Corporate Update (Jun 25, 2025)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed June 25, 2025
Period End
June 24, 2025
Security
ROIV
In the record · 2021–202610-K510-Q168-K82

ROIV filed 5 annual reports (10-K), 16 quarterly reports (10-Q) and 82 current reports (8-K) between 2021 and 2026.

  1. Leadership change8-K · Oct ’21Oct ’21
  2. Leadership change8-K · Nov ’22Nov ’22
  3. Deal closed8-K · Dec ’23Dec ’23
  4. Material agreement8-K · Mar ’26Mar ’26

01—Abstract

Summary

Summary of the 8-K filed June 25, 2025. Cited figures are marked; the original filing is the authoritative source.

Roivant Sciences Ltd. (ROIV) disclosed in this Form 8-K, filed June 25, 2025, that its board of directors authorized on June 24, 2025 a new common share repurchase program of up to $500 milliona (excluding fees and expenses).

The authorization is in addition to the $1.5 billionb repurchase program announced in April 2024, which had approximately $205 million of remaining capacity as of March 31, 2025 and has since been fully exhausted. The new program will be funded with available cash and cash equivalents on hand and has no expiration date. The timing and total amount of repurchases will depend on factors including the market price of the common shares, general business, macroeconomic and market conditions, and other investment opportunities.

Purchases may be made through open market transactions, tender offers, or privately negotiated transactions, including Rule 10b5-1 trading plans. The company may suspend or discontinue the program at any time, and it gives no assurance as to how many shares will be repurchased or at what prices. The filing's only other item is Item 9.01, which lists a Cover Page Interactive Data File (Inline XBRL) as the exhibit.

02—Key points

Key Highlights

  1. Board authorized a new common share repurchase program of up to $500 million (excluding fees and expenses) on June 24, 2025.
  2. The new authorization is in addition to the $1.5 billion program announced in April 2024.
  3. The April 2024 program had approximately $205 million of remaining capacity as of March 31, 2025 and has since been fully exhausted.
  4. The new program is funded with available cash and cash equivalents on hand and has no expiration date.
  5. Repurchases may be made via open market transactions, tender offers, or privately negotiated transactions, including Rule 10b5-1 trading plans.
  6. The program may be suspended or discontinued at any time, and there is no assurance of the number of shares repurchased or prices paid.
  7. Filing includes only Item 8.01 (Other Events) and Item 9.01 (Exhibits), with the exhibit being the Cover Page Interactive Data File.

03—Questions

Frequently Asked Questions

  1. How large is the new share repurchase authorization?

    The board authorized repurchases of common shares in an aggregate amount of up to $500 million, excluding fees and expenses.

  2. How does this relate to the company's earlier buyback program?

    The new authorization is in addition to the $1.5 billion program announced in April 2024. That earlier program had approximately $205 million of remaining capacity as of March 31, 2025 and has since been fully exhausted.

  3. How will the repurchases be funded?

    The program will be funded with available cash and cash equivalents on hand.

  4. How long will the repurchase program last?

    The program does not have an expiration date, but it may be suspended or discontinued at any time.

  5. Is the company required to buy back a specific number of shares?

    No. The timing and total amount depend on factors such as the market price of the shares, business, macroeconomic and market conditions, and other investment opportunities, and the company gives no assurance as to how many shares it will repurchase or at what prices.

04—Continue

← View all 8-K filings